CD274 and breast carcinoma: With regard to our observation that suboptimal levels of SNS-032 inhibitor also upregulated PD-L1 expression by the surviving TNBC cells, it is possible that this inhibitor can exert pro-tumoral effects, by increasing the chance of PD-L1 expressing breast cancer cells to engage with immune cells in tumors and impair their activation.